论文部分内容阅读
常咯啉是我国首创的一种新型抗心律失常药物,是在中药常山成份常山乙素的结构改造过程中研制成功的。化学名为4—<3′,5′—双[(N—吡咯烷基)甲基]—4′羟苯胺基>喹唑啉。据上海地区常咯啉临床研究协作组观察,总有效率为80.8%,我组在1977年也治疗观察了少数病例,疗效极为良好。78年以来我们又治疗观察了39例,其中男性22例,女性
As a novel anti-arrhythmic drug pioneered by our country, it has been successfully developed in the process of structural modification of Changshan B, a traditional Chinese medicine. Chemical name is 4- <3 ’, 5’-bis [(N-pyrrolidinyl) methyl] -4’hydroxyanilino> quinazoline. According to Shanghai Colchicin Clinical Research Collaboration observed that the total effective rate was 80.8%, our group also treated in 1977 observed a few cases, the effect is extremely good. For the past 78 years, we have treated another 39 patients, of whom 22 were males and females